Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QX027N is a long-acting bispecific monoclonal antibody that targets both human thymic stromal lymphopoietin (TSLP) and human interleukin-13 (IL-13).[6][9] The drug has been engineered with an extended half-life to enable less frequent dosing compared to existing biologics.[6] Through dual, long-acting inhibition of these well-validated inflammatory targets, QX027N is designed to provide deeper and more durable disease control in respiratory and dermatological conditions.[6][9] Developed by Qyuns Therapeutics, it represents a significant advancement in the company's bispecific antibody pipeline for autoimmune and allergic diseases.[3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on QX027N.